Trial Profile
A Multicenter, Open-label, Randomized Pilot Clinical Study of Efficacy and Safety of Reparixin for Prevention of Early Allograft Dysfunction in Patients Undergoing Orthotopic Liver Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Reparixin (Primary)
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Sponsors Dompe Farmaceutici
- 23 Jul 2018 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 New trial record